Corcept Therapeutics Inc (CORT) オプション

Canaccord Genuity⬆️the PT on $CORT to $130 was $78 and reiterated at a Buy rating after they recently had the opportunity to catch up with the management team at Corcept.

Canaccord said it sees strong likelihood of relacorilant approval for Cushing's in 2025, they believe Ph3 ROSELLA data will impress in 1Q25, and CATALYST data will continue to drive Cushing's franchise.

Canaccord additionally said in its note to investors:
"With much being delivered both clinically and on the revenue front in 2024, we believe 2025 is on track to be a robust year as well. With 4Q and FY2024
earnings likely to be released at the end of February (using last year as a guide), we have taken this opportunity to complete some model maintenance and put more thought into our out-year Cushing's franchise estimates. The result of our model updates results in our 12-month price target increasing to $130 from $78."

CORT 1 yr

CORT over $20

Chief Judge of District Court in Camden, New Jersey entered an order that TEVA’s ANDA did not infringe 2 patents owned by CORT under 35 U.S.C. 271.

The Fed. Cir. affirmed the decision of the PTAB that Teva’s evidence did not establish, prima facie, that the claims of the Corcept patent recited subject matter that would have been obvious to one of ordinary skill in the art. 12/7/2021.

On 8/24/21, a class action survived a motion to dismiss and that action is now in settlement mediation. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Corcept had improperly paid doctors to promote its drug Korlym; (2) Corcept aggressively promoted Korlym for off-label uses; (3) Corcept’s sole specialty pharmacy was a related party; (4) Corcept artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices were reasonably likely to lead to regulatory scrutiny; and (6) as a result, defendants’ positive statements about Corcept’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

Longer term holders may be able to seek corporate governance reforms and an incentive award where appropriate.

to learn more, contact jgrabar@grabarlaw.com

My puts took a hit today. Should pull back down before the 18th...
The movment is strange. It appears that its being held at 20 by the MM

only retail sheep buying this

Lmao

TO THE MOON

unsustainable

* * $CORT Video Chart 09-02-2020 * *

Link to Video - click here to watch the technical chart video

* * $CORT Video Chart 02-05-2019 * *

Link to Video - click here to watch the technical chart video

I've got this on my watchlist to see the shorts.

It's their only marketed drug and it's main use is to abort (morning after pill). However, they market it for Cushing's Syndrome (a rare disease). I wonder why?

Might want to take a deeper look into this and see how this could affect the price on this stock in the coming week

https://www.naturalnews.com/2018-09-20-kavanaugh-accuser-christine-blasey-exposed-for-ties-to-big-pharma-abortion-pill-maker.html#

can you post detail info , thanks

Ugly. Patent being tested in Courts by TEVA.. Generics coming Q1:19: 2B market Cap not sustainable...

took all off on that last $18.00 attempt and fail. made .90 on on my average

don't like the lower highs on the chart. will see

Article on Corcept here, April 10, 2018 Washington Post Health and Science:

https://www.washingtonpost.com/

https://search.yahoo.com/yhs/search;_ylt=AwrJ3UpIQc5aY04AaTMPxQt.;_ylc=X1MDMjExNDcwMDU1OQRfcgMyBGZyA3locy1wdHktcHR5X2VtYWlsBGdwcmlkAwRuX3JzbHQDMARuX3N1Z2cDMARvcmlnaW4Dc2VhcmNoLnlhaG9vLmNvbQRwb3MDMARwcXN0cgMEcHFzdHJsAzAEcXN0cmwDMTE2BHF1ZXJ5A1dhc2hpbmd0b24lMjBQb3N0JTIwQXByaWwlMjAxMCUyQyUyMDIwMTglMjBDb3JjZXB0JTIwRHJ1ZyUyMGZvciUyMHRyZWF0aW5nJTIwSGFsbHVjaW5hdGlvbnMlMjBIZWFsdGglMjBhbmQlMjBTY2llbmNlBHRfc3RtcAMxNTIzNDY3MjY1?p=Washington+Post+April+10%2C+2018+Corcept+Drug+for+treating+Hallucinations+Health+and+Science&fr2=sb-top&hspart=pty&hsimp=yhs-pty_email¶m1=20180226¶m2=72ec8054-12ad-4efd-98b7-d333742230e3¶m3=email_1.1~US~appfocus1¶m4=g-lp0-bb9~Chrome~Washington+Post+Corcept+Health+and+Science&type=em_appfocus1_cr

breakout territory - 10day chart looking good

Nice move last week or so. Back Green.. should keep going

Great Move, Great Chart

My new Home of future Profits

CORT's pipeline is valued at zero. In fact, it's pipeline is outrageous. Right now it's being underpriced as solely a Cushing's Disease drug.

missed that Pop, but bought back at open yesterday. story just getting started. Great Longer term hold

and OUT $15.65 that big candle dip to 15.30 was alarming. not looking very solid yet. will sit on sidelines for better entry

Starter $15.82

See Acad-Pharm.com for PR re phase 2 CTAD PR... news relating to dementia related psychosis treatment results with its BTD medication that is already approved for PD- related psychosis. CORT sp negative past few days...we hold both CORT and ACAD.

http://alanhobbes.blogspot.co.uk/2017/05/corcept-therapeutics-cort-q1-2017.html?view=flipcard

When should we look for new test results the rest of this year? What data is expected to be released from on going trials?

Another board for CORT:

https://www.investorvillage.com/smbd.asp?mb=921&pt=m

A number of former AMLN SHs followed Wilson money to CORT

New to CORT. Looking for thoughts as to the next big catalysts and timing for them. Any thoughts? Also looking for other CORT message boards. Does anyone know of other boards where CORT is discussed?

CORT: One of four----

https://www.fool.com/investing/2017/05/11/4-of-the-cheapest-biotech-stocks-in-the-world.aspx

Great ER today looking for $11 this week!

3rd qtr....profitable. Long term 10k holding from 2009.

http://ih.advfn.com/p.php?pid=nmona&article=72810364&symbol=CORT

CORT bullish 5.86

macd crossed above 0
price crossed above resistance
hidden bullish divergence



normal chart


log chart

$CORT recent news/filings

bullish 5.19
moving average support

## source: finance.yahoo.com

Wed, 02 Dec 2015 13:00:01 GMT ~ BioLineRx (BLRX) Worth Watching: Stock Rises 11.3%


read full: http://finance.yahoo.com/news/biolinerx-blrx-worth-watching-stock-130001295.html
*********************************************************

Tue, 01 Dec 2015 13:00:01 GMT ~ Affimed (AFMD) Shows Strength: Stock Moves 6.7% Higher


read full: http://finance.yahoo.com/news/affimed-afmd-shows-strength-stock-130001649.html
*********************************************************

Mon, 23 Nov 2015 21:05:09 GMT ~ SurModics Buys Balloon Catheter Maker Creagh Medical


read full: http://finance.yahoo.com/news/surmodics-buys-balloon-catheter-maker-210509609.html
*********************************************************

Mon, 23 Nov 2015 18:38:06 GMT ~ Pharma Industry Outlook: Pricing Pressure and M&As in Focus


read full: http://finance.yahoo.com/news/pharma-industry-outlook-pricing-pressure-183806341.html
*********************************************************

Fri, 20 Nov 2015 13:15:01 GMT ~ Merus Labs International (MSLI) Jumps: Stock Rises 6.4%


read full: http://finance.yahoo.com/news/merus-labs-international-msli-jumps-131501012.html
*********************************************************

$CORT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CORT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CORT/company-info
Ticker: $CORT
OTC Market Place: Not Available
CIK code: 0001088856
Company name: Corcept Therapeutics, Inc.
Incorporated In: DE, USA


$CORT share structure

## source: otcmarkets.com

Market Value: $583,039,022 a/o Dec 02, 2015
Shares Outstanding: 108,775,937 a/o Oct 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$CORT extra dd links

Company name: Corcept Therapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CORT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CORT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CORT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CORT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CORT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/news - http://finance.yahoo.com/q/h?s=CORT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CORT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CORT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CORT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CORT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CORT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CORT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Corcept+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Corcept+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Corcept+Therapeutics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CORT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CORT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CORT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CORT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CORT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001088856&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CORT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CORT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CORT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CORT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CORT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CORT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CORT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CORT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CORT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CORT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CORT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CORT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CORT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CORT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CORT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CORT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CORT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CORT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CORT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CORT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CORT



$CORT DD Notes ~ http://www.ddnotesmaker.com/CORT

Alan Leong's latest:
http://alanhobbes.blogspot.co.uk/search?q=Corcept

$CORT recent news/filings

bullish

## source: finance.yahoo.com

Fri, 22 May 2015 08:38:46 GMT ~ Cortendo Announces Notice of Annual General Meeting

[at noodls] - Cortendo Announces Notice of Annual General Meeting

read full: http://www.noodls.com/view/6779E5F5E925D344BA1E386121DF8944DBB662A3
*********************************************************

Thu, 21 May 2015 20:14:00 GMT ~ CORCEPT THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders


read full: http://biz.yahoo.com/e/150521/cort8-k.html
*********************************************************

Tue, 19 May 2015 06:51:35 GMT ~ Notification of Trade

[at noodls] - Notification of Trade

read full: http://www.noodls.com/view/DCA2A0BD9465F624CB88039645F749CB43BA642F
*********************************************************

Fri, 15 May 2015 19:25:07 GMT ~ Corcept Therapeutics' Korlym Positive in Breast Cancer Study - Analyst Blog


read full: http://finance.yahoo.com/news/corcept-therapeutics-korlym-positive-breast-192507149.html
*********************************************************

Fri, 15 May 2015 17:04:14 GMT ~ CORCEPT THERAPEUTICS INC Financials


read full: http://finance.yahoo.com/q/is?s=cort
*********************************************************

$CORT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CORT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CORT/company-info
Ticker: $CORT
OTC Market Place: Not Available
CIK code: 0001088856
Company name: Corcept Therapeutics, Inc.
Incorporated In: DE, USA



$CORT share structure

## source: otcmarkets.com

Market Value: $634,674,364 a/o May 28, 2015
Shares Outstanding: 107,754,561 a/o May 01, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$CORT extra dd links

Company name: Corcept Therapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CORT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CORT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CORT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CORT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CORT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/news - http://finance.yahoo.com/q/h?s=CORT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CORT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CORT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CORT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CORT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CORT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CORT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Corcept+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Corcept+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Corcept+Therapeutics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CORT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CORT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CORT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CORT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CORT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001088856&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CORT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CORT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CORT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CORT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CORT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CORT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CORT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CORT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CORT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CORT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CORT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CORT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CORT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CORT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CORT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CORT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CORT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CORT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CORT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CORT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CORT



$CORT DD Notes ~ http://www.ddnotesmaker.com/CORT

Here is the link to the excellent must-read blog by Alan Leong. A wealth of great ingormation and insights into CORT and many other small to mid cap biotech opportunitues... http://alanhobbes.blogspot.com/?view=magazine&m=1

Good response rate for the 2 of 7 GR+ patients.

Corcept Therapeutics Announces Poster Presentations on Mifepristone
for the Treatment of Patients with Cushing’s Syndrome
at the 27th Annual American Association of Clinical Endocrinologists

Press Release delivered via email

MENLO PARK, Calif. (May 14, 2015) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that four posters about mifepristone will be presented at the 24th annual American Association of Clinical Endocrinologists (AACE) being held at the Music City Convention Center in Nashville, TN from May 13 – 17, 2015.
“We are pleased that physicians have taken a strong interest in mifepristone and its potential to treat patients with Cushing’s syndrome,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.

In addition to presentation of the four abstracts described below, AACE attendees will have the opportunity to attend a “Product Theatre” talk by Ty Carroll, M.D., whose topic will be “Not-So-Subclinical Cushing’s Syndrome.” Corcept is a sponsor of Dr. Carroll’s presentation.

Friday, May 15, 2015

Poster #131: “Resistant metabolic abnormalities prompting Cushing’s syndrome work-up and treatment with mifepristone”
Douglas Beatty, M.D., Rachel Bunta, Dat Nguyen, PharmD

Poster # 840: “Mifepristone re-established glycemic control in a Cushing’s syndrome patient that relapsed after a 21 month interruption”
Todd Frieze, M.D., James Smith, Ph. D.

Product Theater: “Not-So-Subclinical Cushing’s Syndrome”
Ty Carroll, M.D.

Saturday, May 16, 2015

Late-Breaking Poster: “Use of mifepristone in an ectopic Cushing’s syndrome patient pending tumor localization”
Adeela Ansari, M.D., Precious Lim, Ph.D., Dat Nguyen, PharmD

Late-Breaking Poster: “Improved response to octreotide LAR for ectopic Cushing’s syndrome during mifepristone therapy: A case study”
Andreas Moraitis, M.D., Richard Auchus, M.D.

I asked Corcept about the two patients that were partial responders (at least 30% reduction of target tumors' "longest diameter" total) and got the following reply:

. . . of the two responders, both were breast cancer patients (1 was triple negative breast cancer, 1 was classified as metastatic breast cancer).

CORCEPT THERAPEUTICS’ MIFEPRISTONE COMBINED WITH ERIBULIN TO IMPROVE ANTITUMOR ACTIVITY IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER

http://www.marketwatch.com/story/corcept-therapeutics-mifepristone-combined-with-eribulin-to-improve-antitumor-activity-in-patients-with-triple-negative-breast-cancer-2015-05-13

Patients with metastatic breast cancer (five with triple-negative breast cancer) were treated with mifepristone and eribulin at three different dose levels. The study consisted of seven patients with GR-positive tumors, three patients with GR-negative tumors and three patients with unknown GR status. Two partial responses have been observed, both in patients with GR-positive cancer.

The study title shows it includes patients who do not have triple negative breast cancer:

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02014337?term=Triple+Negative+Breast+Cancer+mifepristone&rank=1
In fact, the study accepts Breast Cancer, Ovarian Epithelial Cancer Recurrent, Sarcoma, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell, Prostate Cancer, Prostatic Neoplasms

From the title of the press release, one would assume that of the two partial responses, at least one of them was in TNBC, but it's not entirely clear from the text.

What's clear is that both patients had GR-positive tumors and advanced disease.

From the press release: An additional 20 patients with GR-positive metastatic TNBC will be enrolled into the study’s efficacy phase.

I don't recall getting a notice of that myself---I did get an unexpected credit on my credit card.

Adjusting for CORT's 1 off expense Q1, net revenue increased 36.6% (would have been $12.3M ex-expense). CORT guides a similar Q/Q rate of uptake going forward.

On the phone call referenced in my last post, Robb (CORT CFO) said he hadn't heard Alan shut down BioWatch News. He had great respect for Alan and his research. He said, in his opinion the analyst that now best gets CORT is the MD that comes from FBR.

On April 28, 2015 Bloomberg reported Corcept withdrew Korlym's marketing application in the EU.



I asked Corcept about the withdrawal and Corcept's CFO, Charles Robb responded. He said, Corcept withdrew Korlym for strategic reasons.

If approved in the EU, Korlym would be tied to the price of Mifepristone when used as an abortifacient — at about 1/4 the price Corcept charges in the USA for Cushing's.

If Corcept's new compound, 125134 were then later approved for Cushing's, 125134's price would be tied to the lower EU price for Korlym.

By withdrawing Korlym, if and when 125134 is approved for Cushing's, there will be less for the EU to use to limit the sales price of 125134.

By withdrawing Korlym, Corcept can fully enroll the trials for 125134 in the EU, without cannibalizing paying patients.

I didn't ask whether or not the withdrawl would affect their revenue guidance for the year but during the conference call, Corcept reaffirmed their earlier guidance $47–53M.

$CORT recent news/filings

bullish
quick trade

## source: finance.yahoo.com

Mon, 06 Apr 2015 22:20:22 GMT ~ Nasdaq stocks posting largest percentage increases

[AP] - A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: Tonix Pharma rose 26.5 percent to $7.40. Trillium Therapeutic rose 16.4 percent to $11.12. Ebix Inc. rose 14.3 percent to ...

read full: http://sg.finance.yahoo.com/news/nasdaq-stocks-posting-largest-percentage-220237991--finance.html
*********************************************************

Thu, 02 Apr 2015 20:07:15 GMT ~ CORCEPT THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure


read full: http://biz.yahoo.com/e/150402/cort8-k.html
*********************************************************

Thu, 02 Apr 2015 18:41:06 GMT ~ Corcept's Warrants Exercised, Invest in Korlym, Pipeline - Analyst Blog


read full: http://finance.yahoo.com/news/corcepts-warrants-exercised-invest-korlym-184106541.html
*********************************************************

Wed, 01 Apr 2015 21:20:21 GMT ~ Warrant Exercises Generate $17.2 Million; Proceeds to Advance Next-Generation Compounds and Support Commercialization of Korlym®

[at noodls] - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders ...

read full: http://www.noodls.com/view/BC11E4D0C0331300803839A1482C972268EBFA1A
*********************************************************

Wed, 01 Apr 2015 20:05:00 GMT ~ Warrant Exercises Generate $17.2 Million; Proceeds to Advance Next-Generation Compounds and Support Commercialization of Korlym(R)

[Marketwired] - Corcept Therapeutics Incorporated , a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating ...

read full: http://finance.yahoo.com/news/warrant-exercises-generate-17-2-200500765.html
*********************************************************

$CORT charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CORT company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CORT/company-info
Ticker: $CORT
OTC Market Place: Not Available
CIK code: 0001088856
Company name: Corcept Therapeutics, Inc.
Incorporated In: DE, USA

$CORT share structure

## source: otcmarkets.com

Market Value: $583,080,188 a/o Apr 06, 2015
Shares Outstanding: 101,405,250 a/o Mar 02, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$CORT extra dd links

Company name: Corcept Therapeutics, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CORT/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CORT/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CORT+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CORT+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CORT+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/news - http://finance.yahoo.com/q/h?s=CORT+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CORT/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CORT/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CORT/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CORT/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CORT/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CORT+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CORT
DTCC (dtcc.com): http://search2.dtcc.com/?q=Corcept+Therapeutics%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Corcept+Therapeutics%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Corcept+Therapeutics%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CORT/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CORT
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CORT/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CORT/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CORT/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001088856&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CORT/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CORT/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CORT&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CORT
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CORT+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CORT+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CORT
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CORT
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CORT+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CORT/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CORT+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CORT.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CORT
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CORT/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CORT/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CORT/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CORT/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CORT
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CORT
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CORT:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CORT
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CORT



$CORT DD Notes ~ http://www.ddnotesmaker.com/CORT